recognised 15 years earlier, but it was not until 1%96 that the life cycle of this protozoan parasite was understood, with the discovery that the definitive host : was any member of the cat family (fig 1) . ' 2 _ Despite extensive clinical and epidemiological' reporting toxoplasmosis had a relatively low profile until the 1980s, since when it has attracted interest for two reasons. Firstly, it is an important cause of mortality and morbidity in HIV infected patients; secondly, the possibility of preventing or ameliorating its congenital form in the United Kingdom through introduction of a prenatal screening programme Tissue cyst ofToxoplasma gondii in myocardium became the subject of professional and then public debate.3'8 This review will focus mainly on the second or transplacentally. After initial acquisition there is a issue because a recently published report by a multi-parasitaemia and widespread dissemination throughdisciplinary working group has recommended that out the body. The acute stage of the infection then programme cannot reliably be weighed against those of studies conducted in the Netherlands and the United disability and handicap potentially prevented. States which together included 22 neonates with Diagnostic suspicion of congenital infection is likely congenital toxoplasmosis who were asymptomatic or to be high among infants presenting with one or more had non-specific symptoms, who were followed for up of the signs of the classic triad, and theoretically the to 20 years: 17 developed retinochoroiditis, of whom size of the problem of symptomatic congenital toxo-six had visual impairment but none were blind; five plasmosis in England and Wales should be measurable had neurological sequelae, which was significant and with the national voluntary laboratory reporting persistent in only one.30 31 system. The limitations of this routine data source,
The dangers of extrapolating from such a small however, were highlighted several years ago,26 one sample are obvious, but, paradoxically, there are difficulty being that there is no single laboratory test problems in studying this aspect of congenital which will identify all cases of congenital toxo-toxoplasmosis. Most important is the difficulty of plasmosis in infancy, even those in which symptoms prospectively identifying sufficient numbers of are present.
asymptomatically infected neonates for follow up and The prevalence of symptomatic congenital toxo-the need to follow such cases for many decades. The plasmosis at birth in the United Kingdom has therefore alternative is retrospective measurement of the burden been estimated.6 27 The estimates are based, firstly, on of visual disability caused by congenital toxoplasmosis French studies-conducted up to three decades ago by recruiting patients with visual symptoms. Howwhich suggested that fetal toxoplasma infection occurs ever, this approach is complicated by appreciable in about 40-50% of untreated maternal infections and difficulties in conclusively diagnosing toxoplasmic that about 10% of infected neonates have severe disease retinochoroiditis in otherwise healthy children and evident at birth or in the first year of life, with adults.32 Nevertheless, even if several hundred subinvolvement of the central nervous system,'2 and, clinically infected infants are born each year in the secondly, on survey data on the incidence ofgestational United Kingdom, would the substantial financial and toxoplasmosis (about two per 1000 -pregnancies) in clinical costs of a national screening programme be three areas of Britain between 1970 and 1988.' 3528 A justified to prevent visual impairment which may figure of about 50-70 seriously affected births a year in remain uniocular and which may not appear until England and Wales can thus be derived. As these adulthood, even old age? would all be babies with significant damage to the central nervous system and eye involvement the SUITABILITY OF SCREENING TESTS burden of disability could be considerable. This
The burden of physical and emotional harm which estimated figure differs substantially, however, from would be caused by screening is as unquantifiable as that (14, not all with involvement of the central that due to congenital toxoplasmosis, but concerns nervous system) observed in 12 months during 1989-may be identified, which mainly centre on the testing 90, when paediatricians were asked to report cases of and diagnostic procedures. Contrary to expectations symptomatic congenital toxoplasmosis to the British raised in the public debate, there is no one simple test Paediatric Surveillance Unit (British Paediatric which will correctly identify infection after concepSurveillance Unit, unpublished data).
tion, much less tell a woman what she really wants to A similar discrepancy between observed and know, which is whether her baby is infected and expected numbers was described in Scotland,5 and the damaged. reasons are unknown. It is too large to be explained by Screening programme algorithms which have been underdiagnosis (which is unlikely in these severe cases) proposed for the United Kingdom527 entail measuring and underreporting, and it reflects current ignorance toxoplasma specific IgM at booking and at least once or of the incidence and natural history of gestational twice more during pregnancy. Although this has the toxoplasmosis nationwide in the United Kingdom in advantage of cheapness compared with the French the 1990s (in fact there is some evidence that the system (see below), it has three disadvantages. Firstly, incidence of the infection may be declining). `9 there is the difficulty, described above, of interpreting Even less is known about the short term and long a "positive" result in terms of timing when infection term morbidity among the (estimated) 90% of babies occurred relative to conception. Secondly, even a high with congenital toxoplasmosis who are either asympto-test specificity, such as 94% quoted for one "in house" BMJ VOLUME 305 booking and the test repeated monthly among women trimester abortion. That may be preferable to the birth found to be susceptible to detect seroconversion. This of a baby severely damaged by congenital toxois a more specific method of identifying infection after plasmosis, but the difficulty of predicting severity of conception, especially if the standard of the toxo-the condition makes the balance a fine one; the Paris plasma dye test is used. programme encouraged termination only if there was This approach, however, would be extremely costly both fetal infection and either evidence that maternal in Britain; unlike France (where the reverse is true) infection occurred in early pregnancy or ultrasonoabout 80% of women of childbearing age may be graphic evidence (which may take some time to susceptible and therefore eligible for follow up. develop) of the severe manifestations of congenital Furthermore, the acceptability of frequent testing may toxoplasmosis. ' figure 3 who detailed counselling before screening would temper had a "positive" result on screening and confirmatory those expectations and prevent expression of grief testing would have to face some difficult decisions through litigation. Thirdly, there would be maternal about choosing termination versus chemotherapy. anxiety about the screening and the diagnostic and Detailed pretest counselling would be necessary to decision taking processes, which would be prolonged enable these decisions to be as informed as possible in some cases, and which may themselves have an within the limits of existing knowledge.
adverse effect on the outcome of pregnancy.37 One area of uncertainty would be the risk of Fourthly, there would be the physical complications of transplacental transmission having already occurred at chemotherapy and of termination of pregnancy. Of the time of diagnosis with serious damage to the fetus, course these harms should be weighed against those compared with the risk of terminating a pregnancy due to congenital toxoplasmosis, which would have with either a normal uninfected fetus or an infected been prevented; the crucial question is whether they fetus destined to be an asymptomatic infant. The risk balance, and the answer is unknown. of fetal infection is directly related to duration of gestation at which maternal toxoplasmosis occurs, but CONCERNS ABOUT THE NATURAL HISTORY OF that of severity of its effect is inversely related. I'2 Thus GESTATIONAL TOXOPLASMOSIS it is impossible to give a precise estimate of the risk of A controversial issue, raised briefly in the working an affected baby to women who are positive on testing. group report, centres on questioning an established Some women will therefore inevitably choose termina-belief about the natural history of toxoplasmosis. The tion at the earliest opportunity rather than risk a badly underlying principle of the French and Austrian damaged baby. It was because of this, often unneces-programmes is that congenital toxoplasmosis can result sary, fetal wastage that the Paris programme adopted only from infection first acquired in pregnancy, that the algorithm of offering chemotherapy with spira-latent maternal toxoplasmosis does not pose a threat to mycin followed by fetal blood sampling, as figure 3 the fetus. This principle is based on the observation shows. '5 16 that (until recently) two or more recognised cases of The decision to undergo fetal diagnosis is also congenital toxoplasmosis among siblings had not been difficult because cordocentesis itself carries an intrinsic reported. fetal loss rate of 1-2% even in the best hands; the tragic In recent years, however, with the advent of pregand unnecessary loss of a normal pregnancy in which nancies among transplant recipients and AIDS maternal toxoplasmosis was suspected was recently patients, it is now well documented that reactivation described in detail by the mother involved.35 Although with severe fetal infection can occur in immunono such complications were described by the ex-compromised women.2 38 It seems rash to suppose that perienced investigators in the French series, seven of this never occurs among immunocompetent women, their 42 subjects had to undergo repeat fetal blood and such cases have indeed been reported.239~4' sampling. '5 Furthermore, toxoplasmic retinochoroiditis among Other significant harms to the screened women siblings has been described by several authors.242 As would include the complications of the drug treatment this condition is believed to be nearly always due to (spiramycin is relatively safe, but pyrimethamine and congenital rather than acquired infection (indeed this sulphonamides can have serious unwanted effects) and is one of the arguments for screening) then, clearly, the psychological and physical sequelae of late second symptomatic congenital toxoplasmosis can occur as a result of reactivation (or neonates would prevent or minimise the risk of adverse which has a specificity of about 80%.'7 Moreover, there sequelae. The same blood sample collected from is evidence of considerable variation between laboranewborn babies on to filter paper to test for metabolic tories in the way that this assay is performed and read.49 disorders is used to measure toxoplasma specific IgM. In a population with a prevalence of toxoplasma "Positive" babies are treated with pyrimethamine, antibody of about 20% (such as that of British women sulphonamides, and folinic acid for the first year of life. of childbearing age) over 40% of "positive" latex This is an ingenious approach which is still under agglutination tests will be false, and these women evaluation. There are, however, two major problems. would be incorrectly reassured that they were immune. The first is that, though the efficacy of early neonatal If they subsequently acquired gestational toxotreatment in preventing the sequelae of congenital plasmosis and delivered a damaged infant there could toxoplasmosis is unknown on the one hand (and can be medicolegal implications, quite apart from the only be assessed in such a programme, with prolonged personal tragedy. This scenario illustrates the need for follow up of recruited subjects), on the other, several a well informed medical response to clinical demands asymptomatic infected babies are likely to suffer the generated from outside the health service; the clinician serious side effects from chemotherapy. The second should consult the local microbiologist for information problem is the unreliability of neonatal toxoplasma on the test and if necessary consult further with one of IgM as a predictor of congenital toxoplasmosis. The the toxoplasma reference laboratories. Massachusetts programme cites a figure of 90% sensiSecondly, there are the women who are already tivity. However, other authors quote a lower figure of pregnant and are either "worried well" or have a recent 70% for equally sensitive tests. '7 To overcome this or current history of symptoms compatible with acute problem it has been suggested that neonatal toxo-acquired toxoplasmosis. This is of course a diagnostic plasma IgA may be a better indicator of congenital not a screening situation. It should, however, be clear toxoplasmosis than IgM; this approach, however, has from this review that careful counselling of the patient not yet been evaluated. '7 and her partner about the implications of a "positive" test result is still essential before the investigations begin.
Conclusions
The mainstay of diagnosis of acute acquired toxo-
The multidisciplinary working group report con-plasmosis, in pregnant or non-pregnant subjects, is cluded that a national prenatal screening programme specific antibody measurement as already described, for toxoplasmosis should not at present be introduced although identification of the organism or antigen may in the United Kingdom, mainly because of a lack of be necessary in immunocompromised patients.' 17 The evidence that the benefits would outweigh the risks.9 response of most local laboratories to a request for This is an additional observation to societal concerns diagnosis of suspected acute toxoplasmosis would be to about prenatal screening in general. 445 perform a toxoplasma IgG screen and then to refer The report also outlined a research agenda to address "positive" serum samples to a reference laboratory for some of the gaps in knowledge about prevention, further investigation; however, the option exists for diagnosis, and management of toxoplasmosis which some laboratories to offer diagnosis themselves, using are highlighted in this review. It emphasised that ELISA "kits" for measuring specific IgG and IgM. decisions about screening will need regular review in Practitioners should be wary of this approach because the light of knowledge gained. Meanwhile, the main of the varying reliability of such kits referred to earlier thrust towards preventing congenital toxoplasmosis in this review. will be health education focusing on avoiding consumThe investigation of symptomatic pregnant (or noning undercooked meat and raw goat's milk and on pregnant) patients should reflect the differential diagwashing hands after contact with raw meat, garden nosis of toxoplasmosis, which might include other soil, and cats' litter trays. Information about toxo-causes of "glandular fever," lymphadenopathy, plasmosis and how to avoid it should now be generally or uveitis. Patients who present with isolated available to pregnant women in the United Kingdom lymphadenopathy may come to biopsy: the histological through both central"6 and local initiatives, although picture of toxoplasmic lymphadenopathy is said to be ideally it should also be targeted at women planning to characteristic, although the organisms or tissue cysts become preguant or girls still at school.
are only rarely seen.'2 17 Those who present with uveitis
If advocates of screening are not influenced by should be seen by an ophthalmologist and should also the arguments of the working group then pressure be investigated serologically by a reference laboratory to introduce a programme is likely to continue, because clinical diagnosis is not always reliable.32 The Unfortunately, public campaigns may create demand most difficult cases will be in pregnant women with without the appropriate health service infrastructure vague, non-specific symptoms with an uncertain date of being in place to deal effectively with it (for example, onset: consultation with the local microbiologist and, if medical education; validated test algorithms; fetal necessary, the reference laboratory microbiologist is diagnostic expertise; counselling; and laboratory, essential and is an integral part of management. obstetric, and paediatric resources). Currently, women Arguments about the pros and cons of screening often become polarised; 15 years ago Sackett and Holland described the protagonists as "evangelists" and "snails."50 Up to now the evangelists have held the limelight over the issues of prenatal screening for toxoplasmosis. This review has attempted to redress the balance by taking account of the snails' view of the subject and by outlining alternative approaches to preventing the damage which toxoplasma can cause. 
ANY QUESTIONS
What are the risks ofcardiovascular complications in a patient receiving weekly intravenous injections of 10 ml of 15% magnesium sulphate?
Ten millilitres of 15% magnesium sulphate contains 6 mmol of magnesium (1-5 g). The dose administered as an intravenous bolus to control cardiac arrhythmia is 4-12 mmol. A bolus of 8 mmol of magnesium sulphate results in a doubling of the serum concentration, which returns to the normal range (0 7-1 1 mmol/1) within 20 minutes by a combination of renal clearance and redistribution.' Cardiac toxicity has not been reported after boluses of 4-12 mmol of intravenous magnesium for cardiac arrhythmia, even when followed by an intravenous infusion of 60 mmol over 24 hours (serum magnesium concentration 1-6-2-0 mmolIl at the end of the infusion).
All patients report a feeling ofcutaneous warmth during rapid bolus administration of magnesium, akin to that after injection of radiological contrast; a transient small fall in mean blood pressure results. Slow intravenous injection does not result in any haemodynamic sequelae. Cardiac toxicity is evident only when the serum magnesium concentration rises in excess of 4 mmol/l, at which time sinus bradycardia and increasing atrioventricular block are seen.2 Coma and death from respiratory depression supervene at serum concentrations of 6 mmol/l. latrogenic magnesium toxicity is largely confined to children treated with frequent magnesium sulphate enemas and is rarely seen. The symptoms are predominantly neurological with drowsiness, irritability, coma, and muscle weakness; electrocardiographic changes or cardiac toxicity, or both, are not reported.
The average oral intake ofmagnesium is 5-12 mmol/day, roughly a third of which is absorbed in the small bowel under the influence of vitamin D. Urinary excretion is 3-5 mmol/day in magnesium balance.3 Unless renal function is impaired a weekly dose of 6 mmol is unlikely to result in an appreciable accumulation of magnesium. BMJ VOLUME 305
